MedStar Health Type 2 Diabetes Pathway to Control (T2DMBC)
Type 2 Diabetes Mellitus, Hyperglycemia
About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Diabetes Care Management, Chronic Care Model, Resources Utilization, Hemoglobin A1C, Hospitalizations, Emergency Room Visits, Cost analysis, Return on Investment
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of type 2 diabetes for >=1 year
- Active practice patient
- A1C > 9.0% at their last visit to Medical Home, ED or hospital admission plus one more high risk factor (ED visit or hospitalization in past 12 mos)
- Primary Care Provider willing to have patient enter the program
- Patient is able and willing to participate in the program and exhibits readiness to change DM self-management
- Proficient in English
Exclusion Criteria:
- Known history of DKA
- No MedStar PCP visit within past 12 months
- Endocrine or Diabetes Education consult referral order in the past 6 months which resulted in Endo visit(s) or DSME visit(s) documented in chart or self-reported by patient during initial screen
- Active additional medical issues which in the opinion of the care team would preclude concentrating on BG control and/or would predispose to ED visits and/or hospital admits independent of glycemic control, e.g.: severe CHF, severe COPD; severe mental illness.
- Resident of skilled nursing facility, nursing home or receiving home health care services.
- Active cancer in the preceding 3 years excluding nonmalignant basal cell cancer
- Supraphysiologic doses of glucocorticoids (hydrocortisone > 30mg/day; prednisone > 5-6mg daily; dexamethasone > 2mg daily).
- Pregnant or anticipates attempting conception in the following year
- Patient and/or custodial caregiver unwilling and/or unable to participate in program-related activities
Sites / Locations
- MedStar Washington Hospital Center
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Intervention
Matched controls
Patients receive the full diabetes pathway intervention consisting of: individualized diabetes self-management education and support; T2DM meds management by clinician-supervised diabetes educators using an evidence-based algorithm and FDA approved anti-hyperglycemic agents; near, real-time blood glucose monitoring, delivered via a combination of two in-person and weekly remote (telephone/text) visits.
Patients receive standard of care from their primary care provider. Usual care visits are typically conducted quarterly per national guidelines for management of T2DM in adults, or more frequently as needed.